Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting

Myriad Genetics (MYGN) will present data from seven new research studies at the 2025 ASCO Annual Meeting, highlighting the potential of its Precise MRD test for cancer recurrence detection. Interim results from the MONSTAR-SCREEN-3 study showed 100% baseline ctDNA detection across various tumor types, with detection of tumor fractions as low as 0.0001% and earlier recurrence detection compared to imaging. Myriad also plans to launch an AI-powered Prolaris prostate cancer test and an expanded MyRisk gene panel later this year, integrating its oncology portfolio with Flatiron's OncoEMR and Epic platforms.

Analysis

Myriad Genetics (MYGN) is poised to present significant clinical data at the 2025 ASCO Annual Meeting, underscoring advancements in its molecular diagnostic portfolio. Notably, interim results from the MONSTAR-SCREEN-3 study for its Precise MRD (Molecular Residual Disease) test demonstrated 100% baseline detection of circulating tumor DNA (ctDNA) across diverse tumor types, including those traditionally challenging to assess. The study highlighted the test's ultra-sensitivity, detecting tumor fractions as low as 0.0001% and providing a lead time in identifying recurrence compared to standard imaging. This WGS-based personalized ctDNA panel is a key component of Myriad's strategy to advance precision oncology. Further strengthening its pipeline, Myriad anticipates the commercial launch of Precise MRD in 2026. Additionally, the company plans to launch an AI-powered Prolaris prostate cancer prognostic test in early 2026, an expanded MyRisk hereditary cancer gene panel later this year, and complete EMR integrations with Flatiron’s OncoEMR and Epic platforms for its full oncology portfolio within the current year. These developments, coupled with a new brand identity for Myriad Oncology, signal a focused effort on innovation and market penetration within the oncology diagnostic space.

Key Decisions for Investors

• Investors should monitor the detailed data presentations at the ASCO Annual Meeting, particularly for the MONSTAR-SCREEN-3 study, to further assess the clinical validation and competitive positioning of the Precise MRD test.
• The planned commercial launch of Precise MRD in 2026 and the AI-enhanced Prolaris test in early 2026 represent key potential catalysts for revenue growth; track progress towards these launches and early adoption rates.
• Consider the successful EMR integration later this year as a positive operational development that could enhance test accessibility and clinician workflow, potentially driving increased utilization of Myriad's oncology portfolio.
• Given the strongly positive sentiment and the promising pipeline developments, particularly in high-growth areas like MRD testing and AI-driven diagnostics, current positions may warrant a bullish re-evaluation, while new investors could explore entry points pending ASCO data outcomes.